Boro Dropulić

6.5k total citations · 1 hit paper
95 papers, 3.2k citations indexed

About

Boro Dropulić is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Boro Dropulić has authored 95 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 49 papers in Molecular Biology and 29 papers in Genetics. Recurrent topics in Boro Dropulić's work include CAR-T cell therapy research (54 papers), Virus-based gene therapy research (29 papers) and CRISPR and Genetic Engineering (23 papers). Boro Dropulić is often cited by papers focused on CAR-T cell therapy research (54 papers), Virus-based gene therapy research (29 papers) and CRISPR and Genetic Engineering (23 papers). Boro Dropulić collaborates with scholars based in United States, Germany and Russia. Boro Dropulić's co-authors include Rimas J. Orentas, Dina Schneider, Laurent Humeau, Gwendolyn K. Binder, Vladimir Slepushkin, Xiaobin Lü, Kuan-Teh Jeang, Carl H. June, Winfried Krueger and Bruce L. Levine and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Boro Dropulić

92 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

2020 318 citations Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Boro Dropulić United States	30	1.7k	1.7k	1.3k	639	574	95	3.2k
Gabriela Plesa United States	26	1.8k 1.1×	2.9k 1.7×	1.3k 1.0×	1.4k 2.1×	449 0.8×	45	4.5k
Gwendolyn K. Binder United States	15	1.1k 0.6×	1.3k 0.8×	1.0k 0.8×	629 1.0×	276 0.5×	20	2.3k
David DiGiusto United States	20	1.2k 0.7×	1.3k 0.8×	766 0.6×	1.0k 1.6×	271 0.5×	49	2.8k
Christopher Baum Germany	39	3.8k 2.3×	1.5k 0.9×	3.0k 2.3×	662 1.0×	305 0.5×	95	5.1k
Gwenn Danet-Desnoyers United States	21	1.2k 0.7×	1.6k 1.0×	711 0.5×	1.1k 1.8×	87 0.2×	38	3.1k
Omkar U. Kawalekar United States	13	1.3k 0.8×	3.1k 1.9×	768 0.6×	1.8k 2.8×	78 0.1×	20	4.5k
Joyce Chen United States	9	610 0.4×	924 0.6×	328 0.3×	1.0k 1.6×	358 0.6×	20	2.0k
Carmine Carpenito United States	22	1.6k 1.0×	4.3k 2.6×	1.4k 1.1×	2.8k 4.4×	151 0.3×	37	5.8k
Éric Yvon United States	11	1.7k 1.0×	1.6k 1.0×	1.8k 1.3×	995 1.6×	45 0.1×	18	3.3k
Troy Brady United States	15	1.1k 0.6×	492 0.3×	534 0.4×	385 0.6×	797 1.4×	17	1.9k

Countries citing papers authored by Boro Dropulić

Since Specialization

Citations

This map shows the geographic impact of Boro Dropulić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boro Dropulić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boro Dropulić more than expected).

Fields of papers citing papers by Boro Dropulić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boro Dropulić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boro Dropulić. The network helps show where Boro Dropulić may publish in the future.

Co-authorship network of co-authors of Boro Dropulić

This figure shows the co-authorship network connecting the top 25 collaborators of Boro Dropulić. A scholar is included among the top collaborators of Boro Dropulić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boro Dropulić. Boro Dropulić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orentas, Rimas J., Boro Dropulić, & Marcos de Lima. (2023). Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges. Seminars in Hematology. 60(1). 20–24. 16 indexed citations

Hong, Changjin, Boro Dropulić, Paolo F. Caimi, et al.. (2022). Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma. Cancer Discovery. 12(8). 1886–1903. 52 indexed citations

Knight, Jennifer M., Anikó Szabó, Sharon Yim, et al.. (2022). Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. SHILAP Revista de lepidopterología. 2(1). 49–49. 9 indexed citations

Adair, Jennifer E., Lois Bayigga, Rimas J. Orentas, et al.. (2022). Place-of-care manufacturing of gene therapies. The Lancet Haematology. 9(11). e807–e808. 4 indexed citations

Alabanza, Leah, Ying Xiong, Bang K. Vu, et al.. (2022). Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β. Frontiers in Immunology. 13. 832645–832645. 41 indexed citations

Arunachalam, Arun Kumar, Uday Kulkarni, Anu Korula, et al.. (2022). Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. Bone Marrow Transplantation. 58(2). 160–167. 58 indexed citations

Shah, Nirav N., Joanna Zurko, Timothy S. Fenske, et al.. (2021). Clinical and Manufacturing Outcomes of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 and IL-15. Transplantation and Cellular Therapy. 27(3). S194–S195. 1 indexed citations

Paugh, Barbara S., Lajos Baranyi, André Roy, et al.. (2021). Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells. Scientific Reports. 11(1). 389–389. 16 indexed citations

Shah, Nirav N., Bryon D. Johnson, Dina Schneider, et al.. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine. 26(10). 1569–1575. 318 indexed citations breakdown →

10.

Bari, Rafijul, Markus Granzin, Kam Sze Tsang, et al.. (2019). A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy. Frontiers in Immunology. 10. 2001–2001. 72 indexed citations

11.

Shah, Nirav N., Fenlu Zhu, Dina Schneider, et al.. (2019). Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 4465–4465. 7 indexed citations

12.

Schneider, Dina, Ying Xiong, Peirong Hu, et al.. (2018). A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. Frontiers in Oncology. 8. 539–539. 32 indexed citations

13.

Zhu, Fenlu, Nirav N. Shah, Huiqing Xu, et al.. (2017). Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 20(3). 394–406. 87 indexed citations

14.

Zhu, Fenlu, Nirav N. Shah, Huiqing Xu, et al.. (2016). CAR-T Cell Production Using the Clinimacs® Prodigy System. Blood. 128(22). 5724–5724. 14 indexed citations

15.

Dropulić, Boro. (2011). Lentiviral Vectors: Their Molecular Design, Safety, and Use in Laboratory and Preclinical Research. Human Gene Therapy. 22(6). 649–657. 63 indexed citations

16.

Strayer, David S., Ramesh Akkina, Bruce A. Bunnell, et al.. (2005). Current status of gene therapy strategies to treat HIV/AIDS. Molecular Therapy. 11(6). 823–842. 74 indexed citations

17.

Dropulić, Boro. (1998). Novel lentiviral vectors for human gene therapy. Expert Opinion on Investigational Drugs. 7(6). 997–1001. 1 indexed citations

18.

Dropulić, Boro, Stephen M. Smith, & Kuan‐Teh Jeang. (1994). Activation and Inactivation of Gene Expression Using RNA Sequences. Advances in pharmacology. 30. 247–270. 3 indexed citations

19.

Dropulić, Boro & Kuan-Teh Jeang. (1994). Intracellular Susceptibility to Ribozymes in a Tethered Substrate—Ribozyme Provirus Model Is Not Predicted by Secondary Structures of Human Immunodeficiency Virus Type 1 RNAs in Vitro. PubMed. 4(3). 217–221. 17 indexed citations

20.

Dropulić, Boro & Kuan-Teh Jeang. (1994). Gene Therapy for Human Immunodeficiency Virus Infection: Genetic Antiviral Strategies and Targets for Intervention. Human Gene Therapy. 5(8). 927–939. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact